International Immunology · 1990 · 108 citations · 4 references
Life SciencesImmunologyInfectious DiseasesAdaptive ImmunityCellular ImmunologyClinical ImmunologyCytotoxic T Lymphocyte ResponsesEffector T Cell FunctionLymphocyte ActivationT Cell ActivationT Cell BiologyT Cell DifferentiationCytotoxic Effector FunctionEffector Cytotoxic T Lymphocyte DifferentiationEffector T Cell DifferentiationMemory Cytotoxic T LymphocytesPeripheral Blood Lymphocyte AnalysisT Cell Lineage CommitmentT-cell Immune ResponsesT-cell Immunophenotypes
Human immunodeficiency virus type 1 (HIV-1) specific cytotoxic T lymphocytes (CTL) have been detected in most patients following infection. It has also been suggested that the specific CTL response, which may play an important role in delaying disease in infected humans, may decline during the course of disease progression. We have measured HIV peptide specific CTL precursor frequency by limiting dilution analysis in two healthy seropositive patients whose fresh peripheral blood mononuclear cells (PBM) specifically lysed MHC matched target cells (restricted by HLA B27 and B8 respectively). The frequency of HIV peptide specific CTL precursors is high (3 x 10(-3)-10(-4], but lower than estimates of circulating CTL with the same specific cytotoxic activity present directly in peripheral blood using the same sample (10(-2)-10(-3]. We suggest that this difference may result from terminal effector CTL differentiation in the T cell lineage. This implies that only a subset of CTL effectors have growth potential, whereas relatively higher levels of CTL with lytic activity can be detected in PBM of healthy HIV seropositive patients.
4
HIV-specific cytotoxic T lymphocytes in seropositive individuals
Bruce D. Walker, Sekhar Chakrabarti, Bernard Moss et al. · Nature · 1987 · 783 citations